161 related articles for article (PubMed ID: 27190374)
41. Effect of low versus high dialysate sodium concentration on blood pressure and endothelial-derived vasoregulators during hemodialysis: a randomized crossover study.
Inrig JK; Molina C; D'Silva K; Kim C; Van Buren P; Allen JD; Toto R
Am J Kidney Dis; 2015 Mar; 65(3):464-73. PubMed ID: 25530107
[TBL] [Abstract][Full Text] [Related]
42. Middle molecule removal in low-flux polysulfone dialyzers: impact of flows and surface area on whole-body and dialyzer clearances.
Eloot S; de Vos JY; de Vos F; Hombrouckx R; Verdonck P
Hemodial Int; 2005 Oct; 9(4):399-408. PubMed ID: 16219061
[TBL] [Abstract][Full Text] [Related]
43. Does concomitant administration of sevelamer and calcium carbonate modify the control of phosphatemia?
Ouellet G; Cardinal H; Mailhot M; Ste-Marie LG; Roy L
Ther Apher Dial; 2010 Apr; 14(2):172-7. PubMed ID: 20438539
[TBL] [Abstract][Full Text] [Related]
44. Calcium exposure and removal in chronic hemodialysis patients.
Sigrist M; McIntyre CW
J Ren Nutr; 2006 Jan; 16(1):41-6. PubMed ID: 16414440
[TBL] [Abstract][Full Text] [Related]
45. Effect of gastric acid suppression with pantoprazole on the efficacy of calcium carbonate as a phosphate binder in haemodialysis patients.
Cervelli MJ; Shaman A; Meade A; Carroll R; McDonald SP
Nephrology (Carlton); 2012 Jul; 17(5):458-65. PubMed ID: 22471559
[TBL] [Abstract][Full Text] [Related]
46. Calcium-enriched bread for treatment of uremic hyperphosphatemia.
Babarykin D; Adamsone I; Amerika D; Spudass A; Moisejev V; Berzina N; Michule L; Rozental R
J Ren Nutr; 2004 Jul; 14(3):149-56. PubMed ID: 15232793
[TBL] [Abstract][Full Text] [Related]
47. The Impact of Medical Nutrition Intervention on the Management of Hyperphosphatemia in Hemodialysis Patients with Stage 5 Chronic Kidney Disease: A Case Series.
Moroșan E; Popovici V; Elian V; Dărăban AM; Rusu AI; Licu M; Mititelu M; Karampelas O
Int J Environ Res Public Health; 2023 Mar; 20(6):. PubMed ID: 36981958
[TBL] [Abstract][Full Text] [Related]
48. Reprocessing high-flux polysulfone dialyzers does not negatively impact solute removal in short-daily online hemodiafiltration.
Melo NC; Moyses RM; Elias RM; Castro MC
Hemodial Int; 2014 Apr; 18(2):473-80. PubMed ID: 24393428
[TBL] [Abstract][Full Text] [Related]
49. Effect of Phosphate-Specific Diet Therapy on Phosphate Levels in Adults Undergoing Maintenance Hemodialysis: A Systematic Review and Meta-Analysis.
St-Jules DE; Rozga MR; Handu D; Carrero JJ
Clin J Am Soc Nephrol; 2020 Dec; 16(1):107-120. PubMed ID: 33380474
[TBL] [Abstract][Full Text] [Related]
50. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia.
Joy MS; Finn WF;
Am J Kidney Dis; 2003 Jul; 42(1):96-107. PubMed ID: 12830461
[TBL] [Abstract][Full Text] [Related]
51. Dialyzer clearances and mass transfer-area coefficients for small solutes at low dialysate flow rates.
Leypoldt JK; Kamerath CD; Gilson JF; Friederichs G
ASAIO J; 2006; 52(4):404-9. PubMed ID: 16883120
[TBL] [Abstract][Full Text] [Related]
52. Effect of Tenapanor on Serum Phosphate in Patients Receiving Hemodialysis.
Block GA; Rosenbaum DP; Leonsson-Zachrisson M; Åstrand M; Johansson S; Knutsson M; Langkilde AM; Chertow GM
J Am Soc Nephrol; 2017 Jun; 28(6):1933-1942. PubMed ID: 28159782
[TBL] [Abstract][Full Text] [Related]
53. Iron-magnesium hydroxycarbonate (fermagate): a novel non-calcium-containing phosphate binder for the treatment of hyperphosphatemia in chronic hemodialysis patients.
McIntyre CW; Pai P; Warwick G; Wilkie M; Toft AJ; Hutchison AJ
Clin J Am Soc Nephrol; 2009 Feb; 4(2):401-9. PubMed ID: 19158369
[TBL] [Abstract][Full Text] [Related]
54. Increasing blood flow increases kt/V(urea) and potassium removal but fails to improve phosphate removal.
Gutzwiller JP; Schneditz D; Huber AR; Schindler C; Garbani E; Zehnder CE
Clin Nephrol; 2003 Feb; 59(2):130-6. PubMed ID: 12608556
[TBL] [Abstract][Full Text] [Related]
55. Phosphate kinetics during high-flux hemodialysis.
DeSoi CA; Umans JG
J Am Soc Nephrol; 1993 Nov; 4(5):1214-8. PubMed ID: 8305649
[TBL] [Abstract][Full Text] [Related]
56. A randomized controlled trial of different serum phosphate ranges in subjects on hemodialysis.
Bhargava R; Kalra PA; Hann M; Brenchley P; Hurst H; Hutchison AJ
BMC Nephrol; 2019 Feb; 20(1):37. PubMed ID: 30717691
[TBL] [Abstract][Full Text] [Related]
57. The economic impact of improving phosphate binder therapy adherence and attainment of guideline phosphorus goals in hemodialysis patients: a Medicare cost-offset model.
Ramakrishnan K; Braunhofer P; Newsome B; Lubeck D; Wang S; Deuson J; Claxton AJ
Adv Ther; 2014 Dec; 31(12):1272-86. PubMed ID: 25479935
[TBL] [Abstract][Full Text] [Related]
58. Short-term effects of online hemodiafiltration on phosphate control: a result from the randomized controlled Convective Transport Study (CONTRAST).
Penne EL; van der Weerd NC; van den Dorpel MA; Grooteman MP; Lévesque R; Nubé MJ; Bots ML; Blankestijn PJ; ter Wee PM;
Am J Kidney Dis; 2010 Jan; 55(1):77-87. PubMed ID: 19962805
[TBL] [Abstract][Full Text] [Related]
59. Medium Cut-Off Dialyzer versus Eight Hemodiafiltration Dialyzers: Comparison Using a Global Removal Score.
Maduell F; Rodas L; Broseta JJ; Gomez M; Xipell M; Guillen E; Montagud-Marrahi E; Arias-Guillén M; Fontseré N; Vera M; Rico N
Blood Purif; 2019; 48(2):167-174. PubMed ID: 30943486
[TBL] [Abstract][Full Text] [Related]
60. Effect of varying dialysate bicarbonate concentration on serum phosphate.
Kobrin SM; Raja RM
ASAIO Trans; 1989; 35(3):423-5. PubMed ID: 2597494
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
